When was Marengo founded?

Marengo was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Marengo located?

Marengo is headquartered in Cambridge, United States.

How many employees does Marengo have?

As of Feb 28, 2026, the latest employee count at Marengo is 39.

Is Marengo a funded company?

Marengo is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Nov 08, 2021.

When was the latest funding round of Marengo?

Marengo's latest funding was a $***** Series C round on Nov 08, 2021, with participation from 1 investor.

Where does Marengo rank among its competitors?

Marengo ranks 704th amongst 3241 active competitors, of which 1115 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Marengo?

Marengo's top competitors include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Marengo - 2026 Company Profile, Team, Funding & Competitors

Marengo is a series C company based in Cambridge (United States), founded in 2015. It operates as a Developer of cell therapy for the treatment of cancer. Marengo has raised $80M in funding from Apple Tree Partners. The company has 3241 active competitors, including 1115 funded and 782 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications.

Company Details

Developer of cell therapy for the treatment of cancer. The lead program STAR0602 is an antibody fusion molecule that binds and activates specific T cells to fight tumors by directly targeting Vβ TCR variants to enhance anti-tumor activity. Also, includes STAR0615, STAR2002, SKAR3012, and STAR0602X for solid tumors.

Website: marengotx.com
Social
Email ID: *****@marengotx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Series C

Total Funding

$80M in 1 round

Latest Funding Round

Series C, Nov 08, 2021, $*****

Investors

Apple Tree Partners

Ranked

704^th among 3241 active competitors

Employee Count

39 as on Feb 28, 2026

Similar Companies

Jazz Pharmaceuticals & 3118 more

View Marengo's full profile

Marengo has raised a total funding of $80M over 1 round. Its latest funding round was a Series C round on Nov 08, 2021 for $*****. 1 investor participated in its latest round. Marengo has 1 institutional investor.

Here is the list of recent funding rounds of Marengo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 08, 2021	3439687	Series C	3064712	5123965	3901902	6963936

Access funding benchmarks and valuations. Sign up today!

View details of Marengo's funding rounds and investors

Marengo's employee count trend

Marengo has 39 employees as of Feb 26. Here is Marengo's employee count trend over the years:

Uncover Marengo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Marengo include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Marengo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Vivo Capital & 10 others	79/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	BlackRock, General Atlantic & 50 others	74/100
8th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	Adage Capital Management, Corriente Biotechnology Partners ... & 26 others	72/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
704th	Marengo 2015, Cambridge (United States), Series C	Developer of cell therapy for the treatment of cancer	$80M	Apple Tree Partners	49/100